Company Overview of Civitas Therapeutics, Inc.
Civitas Therapeutics, Inc., a biopharmaceutical company, develops and commercializes transformative therapeutics using its ARCUS technology. Its technology enables the delivery of a precise dose to the lung to potentially enable rapid and predictable L-dopa absorption through a reusable, pocket-size, and breath-actuated inhaler. The company offers CVT-301, a inhaled L-dopa therapy for OFF episodes that provides rapid delivery of L-dopa to the brain to be used in conjunction with a Parkinson’s disease patient’s individually optimized oral L-dopa regimen. Civitas Therapeutics, Inc. was formerly known as Corregidor Therapeutics, Inc. and changed its name to Civitas Therapeutics, Inc. in April 2...
190 Everett Avenue
Chelsea, MA 02150
Founded in 2009
Key Executives for Civitas Therapeutics, Inc.
Co-Founder, Consultant and Director
Co-Founder and Chief Medical Officer
Co-Founder and Chairman of Scientific & Clinical Advisory Board
Compensation as of Fiscal Year 2015.
Civitas Therapeutics, Inc. Key Developments
Acorda Therapeutics, Inc., Civitas Therapeutics, Inc. - M&A Call
Sep 24 14
To discuss entry of Acorda Therapeutics into an agreement to acquire Civitas Therapeutics
Civitas Therapeutics, Inc. Presents at Boston CEO Conference, Jun-04-2014 03:00 PM
Jun 2 14
Civitas Therapeutics, Inc. Presents at Boston CEO Conference, Jun-04-2014 03:00 PM. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, Massachusetts, United States. Speakers: Glenn V. Batchelder, Co-Founder and Director.
Civitas Therapeutics, Inc. Announces Positive Results from A Phase 2B Clinical Trial of CVT-301
Apr 28 14
Civitas Therapeutics, Inc. announced positive results from a Phase 2b clinical trial of CVT-301, an inhaled formulation of levodopa (L-dopa). Study results from Phase 2 studies will be presented at the 66th Annual American Academy of Neurology Meeting on April 29, 2014 at 2:30pm ET in Philadelphia, PA. CVT-301 is being developed as an adjunctive, as-needed therapy to provide rapid and reliable relief from intermittent debilitating motor fluctuations, known as OFF episodes, suffered by Parkinson's disease patients. OFF episodes, which result from the unpredictable nature of oral baseline therapies, affect over half of all patients on an oral L-dopa treatment regimen and are considered to be one of the most important issues facing Parkinson's disease patients. The Phase 2b study was designed to assess the on-demand use of CVT-301 in Parkinson's disease patients experiencing motor fluctuations over a one-month period. The trial evaluated the efficacy, safety and tolerability of two doses of CVT-301. Motor responses were evaluated during regularly-scheduled clinical visits using the Unified Parkinson's Disease Rating Scale Part 3 (UPDRS III). In addition, efficacy was also evaluated during out-patient use with commonly used diary-based outcomes measures. The primary endpoint was successfully met with CVT-301 achieving a clinically important and statistically significant reduction in average UPDRS III motor score versus placebo at time points ranging from 10 to 60 minutes post-administration (p < 0.001). Furthermore, clinically important and statistically significant improvements in UPDRS III were seen at every time point including 10 minutes, the earliest time point tested, for both tested doses. Over the course of the study, patients self-administered CVT-301 as-needed to treat approximately 4,500 OFF episodes, at an average of approximately 2 treatments per day. With self-administration during at-home use, CVT-301 use was not associated with any increase in either non-troublesome or troublesome dyskinesia. All doses of CVT-301 were safe and well-tolerated, and the CVT-301 inhaler was also shown to be easily utilized by Parkinson's disease patients in the OFF state.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|